Cargando...
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s ma...
Guardado en:
| Publicado en: | J Hematol Oncol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4784459/ https://ncbi.nlm.nih.gov/pubmed/26957112 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0250-9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|